BioCorRx Secures U.S. Patent for Biodegradable Naltrexone Implant Technology
核心洞察
BioCorRx Inc. announced the issuance of a new U.S. patent strengthening its intellectual property portfolio for biodegradable naltrexone implant technologies.
The company's investigational BICX104 implant is designed to provide controlled naltrexone delivery and commenced a new clinical study in January 2026 supported by NIDA.
The patent expands BioCorRx's growing portfolio that includes international patents covering naltrexone implants for various therapeutic applications including weight management programs.
BioCorRx Inc. has announced the issuance of a new U.S. patent supporting its biodegradable naltrexone implant technology, marking a significant milestone in the company's intellectual property strategy for addiction treatment solutions. The patent strengthens BioCorRx's growing portfolio of implant-based naltrexone technologies as the company advances clinical development of its investigational BICX104 program.
Patent Portfolio Expansion
The newly issued patent adds to BioCorRx's broader intellectual property portfolio, which includes issued international patents covering additional technologies and potential therapeutic applications involving naltrexone implants. Notably, the company holds an Israeli patent relating to the use of naltrexone implants in weight management programs when combined with behavioral or nutritional counseling. BioCorRx continues to pursue additional patent protection in the United States and internationally for its implant-based naltrexone technologies.
"The issuance of this patent represents an important milestone for BioCorRx and further strengthens our growing intellectual property portfolio relating to implant-based naltrexone technologies," said Lourdes Felix, Chief Executive Officer of BioCorRx Inc. "As we continue advancing development of our implant technology through BioCorRx Pharmaceuticals Inc. (搜索), we believe continued expansion of our patent portfolio supports our long-term strategy around implant-based therapeutic technologies."
Clinical Development Progress
BioCorRx continues to advance development of its implant-based naltrexone technologies through its majority-owned subsidiary, BioCorRx Pharmaceuticals, Inc. The company's investigational BICX104 is a biodegradable naltrexone implant technology designed to provide controlled delivery of naltrexone. A prior clinical study evaluating the company's implant technology was completed in 2023 (ClinicalTrials.gov Identifier: NCT04828694).
A new clinical study evaluating BICX104 commenced in January 2026 (ClinicalTrials.gov Identifier: NCT07269873), with additional studies planned. The current clinical study is supported by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health under Award Number U01DA059994. Prior research evaluating the company's implant technology was also supported in part by the National Institute on Drug Abuse.
Addressing Significant Medical Need
The development comes as opioid use disorder (搜索) represents a major public health challenge. According to the 2023 National Survey on Drug Use and Health, approximately 5.7 million people in the United States aged 12 or older were estimated to have an opioid use disorder in the past year. Opioid use disorder is associated with significant health risks, including overdose, infectious diseases, and increased rates of morbidity and mortality.
Naltrexone is an opioid receptor antagonist that blocks the effects of opioids at the mu-opioid receptor (搜索). It has been approved by the U.S. Food and Drug Administration (FDA) in oral and extended-release injectable forms for the treatment of opioid use disorder (搜索) and alcohol dependence (搜索). By blocking opioid receptors, naltrexone can prevent the euphoric and sedative effects of opioids.
Broader Therapeutic Applications
Beyond opioid use disorder (搜索), BioCorRx's naltrexone implant technology may have applications in other conditions. The company's Israeli patent covers the use of naltrexone implants in weight management programs, addressing another significant public health concern. According to the World Health Organization, approximately 890 million adults worldwide were living with obesity (搜索) in 2022, representing about 1 in 8 people globally.
The World Obesity (搜索) Federation projects that over 1.5 billion adults could be living with obesity by 2035, with the global economic impact of overweight and obesity projected to exceed $4 trillion annually by 2035, driven by obesity-related conditions such as cardiovascular disease, stroke, cancer, and type 2 diabetes.
Company Portfolio
BioCorRx Inc. operates as an addiction treatment solutions company through multiple programs and subsidiaries. The company's Beat Addiction Recovery program includes proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app. Through its subsidiary BioCorRx Pharmaceuticals Inc. (搜索), the company also commercializes LUCEMYRA® (lofexidine), an FDA-approved medication indicated to mitigate opioid withdrawal symptoms in adults.
LUCEMYRA® is a central alpha 2-adrenergic (搜索) agonist that reduces the release of norepinephrine to suppress the neurochemical surge that produces opioid withdrawal. In clinical trials, LUCEMYRA® reduced the severity of withdrawal symptoms compared to placebo, as reported by patients experiencing opioid withdrawal.